Metformin Sustained Release Tablets BP

1. Product Introduction

Metformin Hydrochloride Sustained Release (SR) Tablets are oral biguanide antidiabetic medicines used to improve blood glucose control in adults with type 2 diabetes, alongside diet and exercise. Sustained-release (also described as extended-release or prolonged-release, depending on the approved product) allows metformin to be released gradually and may improve gastrointestinal tolerability for some patients.

Supplied product: each film-coated sustained-release tablet contains Metformin Hydrochloride BP 1 g (1000 mg). Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter by the supplied product information. Facility certification and market-specific registration should be verified before publication or procurement.

2. Product Specifications

3. Manufacturing Technology

Extended-release metformin formulations may employ hydrophilic polymer matrices, including HPMC, to control drug release. The actual matrix composition, manufacturing route, coating, and any gastric-retentive properties depend on the validated product formulation and cannot be assumed from the ingredient label alone.

Manufacturing controls generally cover blend uniformity, compression, coating integrity, moisture exposure, and stability. Specific proprietary processes, including floating tablets or flavor coatings, require manufacturer confirmation.

4. Quality Assurance

Quality assessment of sustained-release tablets includes identity, assay, impurities, content uniformity where applicable, and multi-time-point dissolution testing against the approved product-specific specifications. The correct dissolution limits cannot be inferred from general example profiles.

Nitrosamine risk assessment and any required confirmatory testing should follow current applicable regulatory guidance. Batch-specific certificates of analysis and validated shelf-life evidence should be requested.

5. Why Use Metformin SR?

Metformin reduces hepatic glucose production and improves insulin sensitivity. Compared with immediate-release formulations, extended-release metformin can improve gastrointestinal tolerability in some patients and may simplify administration.

Primary approved use: glycemic control in type 2 diabetes. Uses in prediabetes or polycystic ovary syndrome (PCOS) may be off-label or subject to country-specific guidelines; they should not be presented as universally approved indications.

6. Export and Regulatory Support

For contract manufacturing and export enquiries, request the relevant product registration status, current GMP documentation, Certificate of Analysis, stability data, approved artwork, and any CTD/ACTD dossier availability. COPP, Free Sale Certificates, export authorizations, and shipping terms depend on the destination market and actual documentation.

7. Frequently Asked Questions

Q: What strength is confirmed?
A: The supplied label confirms Metformin Hydrochloride BP 1 g (1000 mg) per sustained-release tablet.

Q: Can I crush or split it?
A: Do not crush or chew sustained-release tablets. Splitting is appropriate only if explicitly permitted in the specific product's approved instructions.

Q: When should it be taken?
A: Follow the prescribed schedule and local product label; many extended-release products are taken with an evening meal, but directions differ by formulation.

Q: What is a “ghost tablet”?
A: Some extended-release formulations may leave an inert tablet shell visible in stool. This does not apply to every formulation.

8. Dosage and Administration

Dosage is individualized by the prescribing clinician based on glycemic response, formulation, kidney function, and tolerance. Treatment is commonly initiated at a lower strength and titrated gradually; a 1000 mg tablet is not necessarily an appropriate starting dose. Maximum daily dose and dosing frequency vary across approved SR products.

Swallow the tablet whole with water unless the specific label explicitly allows splitting. Take with food as directed. Do not substitute SR and immediate-release products without medical advice.

9. Side Effects and Precautions

• Gastrointestinal: nausea, diarrhea, abdominal discomfort, and reduced appetite can occur, especially during initiation.
• Lactic acidosis: rare but serious; risk increases with severe renal impairment, hypoxia, acute illness, and excessive alcohol use. Seek urgent medical attention for concerning symptoms.
• Kidney function: assess eGFR before treatment and periodically. Metformin is contraindicated at eGFR below 30 mL/min/1.73 m²; starting therapy at eGFR 30–45 is generally not recommended under US labeling.
• Vitamin B12: prolonged treatment can lower B12 levels; monitor when clinically indicated.
• Iodinated contrast: temporary interruption is required in certain patients and procedures, not universally before every CT scan. Follow clinician instructions.
• Hypoglycemia: uncommon with metformin alone; risk increases when used with insulin or insulin secretagogues.

10. Storage Instructions

Store according to the approved package label, protected from excessive moisture and heat, in the original packaging. The proposed “below 25°C” condition and 24–36 month shelf life require product-specific stability confirmation.